PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 254 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,329,632 | -22.8% | 141,123 | +0.8% | 0.01% | -16.7% |
| Q2 2023 | $5,611,763 | +100181.7% | 140,049 | +2.1% | 0.01% | -14.3% |
| Q1 2023 | $5,596 | +11.0% | 137,119 | +5.0% | 0.01% | 0.0% |
| Q4 2022 | $5,040 | -99.9% | 130,543 | -0.3% | 0.01% | -30.0% |
| Q3 2022 | $6,964,000 | -4.9% | 130,922 | +4.2% | 0.01% | -9.1% |
| Q2 2022 | $7,325,000 | -18.0% | 125,635 | +7.4% | 0.01% | 0.0% |
| Q1 2022 | $8,930,000 | +34.4% | 117,012 | +6.0% | 0.01% | +37.5% |
| Q4 2021 | $6,644,000 | +8.5% | 110,427 | +1.0% | 0.01% | 0.0% |
| Q3 2021 | $6,121,000 | -19.0% | 109,297 | -12.2% | 0.01% | -20.0% |
| Q2 2021 | $7,558,000 | -14.4% | 124,548 | -1.1% | 0.01% | -16.7% |
| Q1 2021 | $8,831,000 | +17.4% | 125,995 | +0.3% | 0.01% | +20.0% |
| Q4 2020 | $7,520,000 | +5.0% | 125,671 | +5.5% | 0.01% | -9.1% |
| Q3 2020 | $7,161,000 | +0.7% | 119,110 | -12.1% | 0.01% | -8.3% |
| Q2 2020 | $7,111,000 | +50.3% | 135,534 | -3.9% | 0.01% | +20.0% |
| Q1 2020 | $4,730,000 | -25.5% | 141,059 | +0.6% | 0.01% | -9.1% |
| Q4 2019 | $6,351,000 | +30.8% | 140,200 | +9.9% | 0.01% | +22.2% |
| Q3 2019 | $4,855,000 | +92.0% | 127,516 | +119.3% | 0.01% | +80.0% |
| Q2 2019 | $2,529,000 | +21.9% | 58,152 | +6.7% | 0.01% | +25.0% |
| Q1 2019 | $2,075,000 | -11.7% | 54,525 | -0.2% | 0.00% | -20.0% |
| Q4 2018 | $2,351,000 | +27.9% | 54,649 | +46.2% | 0.01% | +25.0% |
| Q3 2018 | $1,838,000 | +43.7% | 37,391 | -6.3% | 0.00% | +33.3% |
| Q2 2018 | $1,279,000 | +6.5% | 39,897 | +3.5% | 0.00% | 0.0% |
| Q1 2018 | $1,201,000 | -33.5% | 38,562 | -2.6% | 0.00% | -25.0% |
| Q4 2017 | $1,807,000 | -4.1% | 39,592 | -21.1% | 0.00% | 0.0% |
| Q3 2017 | $1,884,000 | -19.7% | 50,179 | +2.0% | 0.00% | -20.0% |
| Q2 2017 | $2,347,000 | +8.3% | 49,203 | +3.5% | 0.01% | 0.0% |
| Q1 2017 | $2,167,000 | +46.6% | 47,531 | +3.9% | 0.01% | +25.0% |
| Q4 2016 | $1,478,000 | -1.3% | 45,760 | +4.6% | 0.00% | 0.0% |
| Q3 2016 | $1,498,000 | -0.7% | 43,768 | -2.1% | 0.00% | 0.0% |
| Q2 2016 | $1,508,000 | -34.8% | 44,716 | +2.4% | 0.00% | -42.9% |
| Q1 2016 | $2,314,000 | -29.0% | 43,686 | +2.9% | 0.01% | -30.0% |
| Q4 2015 | $3,261,000 | +101.8% | 42,471 | +8.0% | 0.01% | +100.0% |
| Q3 2015 | $1,616,000 | -40.6% | 39,311 | +2.2% | 0.01% | -44.4% |
| Q2 2015 | $2,721,000 | -23.0% | 38,478 | -3.3% | 0.01% | -10.0% |
| Q1 2015 | $3,535,000 | +19.2% | 39,783 | +19.0% | 0.01% | +11.1% |
| Q4 2014 | $2,965,000 | -12.6% | 33,443 | -4.5% | 0.01% | -10.0% |
| Q3 2014 | $3,393,000 | +5.9% | 35,008 | +0.4% | 0.01% | +11.1% |
| Q2 2014 | $3,203,000 | +48.5% | 34,868 | +13.1% | 0.01% | +50.0% |
| Q1 2014 | $2,157,000 | +15.7% | 30,819 | -5.0% | 0.01% | +20.0% |
| Q4 2013 | $1,864,000 | +32.6% | 32,429 | +10.9% | 0.01% | +25.0% |
| Q3 2013 | $1,406,000 | +68.4% | 29,239 | +1.6% | 0.00% | +33.3% |
| Q2 2013 | $835,000 | – | 28,780 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |